We are live on ! Find out more
NVO

Novo Nordisk

553 hedge funds and large institutions have $8.16B invested in Novo Nordisk in 2018 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 156 increasing their positions, 206 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more call options, than puts

Call options by funds: $51.7M | Put options by funds: $16.3M

8% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 53

0% more funds holding

Funds holding: 552553 (+1)

0.12% more ownership

Funds ownership: 16.76%16.88% (+0.12%)

8% less capital invested

Capital invested by funds: $8.82B → $8.16B (-$665M)

24% less repeat investments, than reductions

Existing positions increased: 156 | Existing positions reduced: 206

26% less funds holding in top 10

Funds holding in top 10: 1914 (-5)

Holders
553
Holders Change
+1
Holders Change %
+0.18%
% of All Funds
12.67%
Holding in Top 10
14
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-26.32%
% of All Funds
0.32%
New
57
Increased
156
Reduced
206
Closed
53
Calls
$51.7M
Puts
$16.3M
Net Calls
+$35.4M
Net Calls Change
+$17.8M

NVO Hedge Fund Activity: Q1 2018 in Review

553 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2018, worth a combined $8.16B — down 7.5% from $8.82B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new NVO positions and 53 closed out — a net gain of 4 holders — while 156 added to existing stakes and 206 trimmed.

The largest buyer was Eaton Vance Management, adding an estimated $79.2M. The largest seller was Folketrygdfondet, cutting an estimated $61.9M.

  • 553 institutional investors held Novo Nordisk (NVO) as of Q1 2018, up from 552 in Q4 2017.
  • Funds reported $8.16B of Novo Nordisk stock for Q1 2018, down 7.5% quarter-over-quarter.
  • 57 funds opened new Novo Nordisk positions in Q1 2018 and 53 closed out, a net change of +4 holders.
  • The largest Novo Nordisk buyer in Q1 2018 was Eaton Vance Management, an estimated $79.2M added.
  • The largest Novo Nordisk seller in Q1 2018 was Folketrygdfondet, an estimated $61.9M sold.

Based on aggregated 13F filings for Q1 2018.